Nuformix plc (LON: NFX)

Market Cap	409.66K
Revenue (ttm)	n/a
Net Income (ttm)	-477.89K
Shares Out	819.31M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,224,635
Open	0.0514
Previous Close	0.0500
Day's Range	0.0450 - 0.0550
52-Week Range	0.0400 - 0.4400
Beta	1.22
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 30, 2024

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3
• Stock Exchange: London Stock Exchange
• Ticker Symbol: NFX